Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Mult Scler Relat Disord ; 52: 103004, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34049217

RESUMO

BACKGROUND: The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread and developed as a pandemic threatening global health. Patients with multiple sclerosis (MS)-an autoimmune demyelinating inflammatory disease of the central nervous system (CNS)-are predominantly treated with immunomodulatory/immunosuppressive disease-modifying therapies (DMTs), which can increase the risk of infection. Therefore, there is concern that these patients may have a higher risk of COVID-19. In response to growing concerns of neurologists and patients, this study aimed to determine the prevalence, severity, and possible complications of COVID-19 infection in patients with MS in Saudi Arabia (SA). METHODS: In this prospective cohort study, demographic and clinical data were obtained from patients residing in SA with MS who had a positive result for COVID-19 per reverse transcription-polymerase chain reaction test or viral gene sequencing, using respiratory or plasma samples. Comparison of COVID-19 severity groups was performed using one-way ANOVA or Kruskal-Wallis test for numerical variables and Chi-squared test for categorical variables. RESULTS: Seventy patients with MS and COVID-19 (71% female) were included in this analysis. Of the 53 (75.7%) patients receiving a DMT at the time of COVID-19 infection, the most frequently used DMTs were fingolimod (25%) and interferon-beta (25%). Nine (13%) patients had MS relapse and were treated with intravenous methylprednisolone in the four weeks before COVID-19 infection. The most common symptoms at the peak of COVID-19 infection were fever (46%), fatigue (37%), and headache (36%). Symptoms lasted for a mean duration of 8.7 days; all symptomatic patients recovered and no deaths were reported. COVID-19 severity was categorized in three groups: asymptomatic (n = 12), mild-not requiring hospitalization (n = 48), and requiring hospitalization (n = 10; two of whom were admitted to the intensive care unit [ICU]). Between the three groups, comparison of age, body mass index , Expanded Disability Severity Score , MS disease duration, and DMT use at the time of infection showed no significant differences. A higher percentage of patients who were admitted to hospital or the ICU (40%; p = 0.026) presented with an MS relapse within the prior four weeks compared with those who were asymptomatic or had a mild infection (both 8.3%). CONCLUSION: These findings present a reassuring picture regarding COVID-19 infection in patients with MS. However, patients with MS who have had a relapse in the preceding four weeks (requiring glucocorticoid treatment) may have an increased risk of severe COVID-19.


Assuntos
COVID-19 , Esclerose Múltipla , Feminino , Humanos , Masculino , Estudos Prospectivos , Sistema de Registros , SARS-CoV-2 , Arábia Saudita
2.
Biomed Pharmacother ; 94: 742-746, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28800543

RESUMO

The present investigation was carried out to evaluate the reduction potential of aqueous extract of casing of pods of phaseolus vulgaris in blood glucose and lipids levels among hyperglycemic streptozotocin (STZ)-induced rats. Oral administration of 150mg/kg of aqueous oral administration of aqueous pod extract of phaseolus vulgaris to diabetic rats for 40days resulted in a significant decrease in blood glucose (p<001), cholesterol (P<0.01) and triglycerides (P<0.01). In addition, glibenclamide reduced blood glucose, cholesterol and triglycerides. It is concluded that both aqueous extract of casing of pods of phaseolus vulgaris and glibenclamide reduced the blood levels of glucose and lipids. In addition, aqueous extract of phaseolus vulgaris pods was more effective than glibenclamide in reducing blood glucose.


Assuntos
Hipoglicemiantes/farmacologia , Hipolipemiantes/farmacologia , Phaseolus/química , Extratos Vegetais/farmacologia , Administração Oral , Animais , Glicemia/efeitos dos fármacos , Colesterol/sangue , Diabetes Mellitus Experimental/tratamento farmacológico , Hiperglicemia/tratamento farmacológico , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/isolamento & purificação , Hipolipemiantes/administração & dosagem , Hipolipemiantes/isolamento & purificação , Lipídeos/sangue , Extratos Vegetais/administração & dosagem , Ratos , Ratos Wistar , Estreptozocina , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA